menu search

Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

Neuronascent to Present Further NNI-362 Phase1a Data  at CTAD 2022 for Alzheimer’s Disease
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) — Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures” has been accepted for a poster presentation at 15th Clinical Trials on […] The post Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease appeared first on... Read More
Posted: Nov 8 2022, 11:00
Author Name: forextv
Views: 112223

Search within

Pages Search Results: